| |
|
|
|
|
|
|
|||
|
HEMOSTASIS, THROMBOSIS, AND VASCULAR BIOLOGY
From the Division of Cardiology, Ospedale Maggiore and
University of Parma, Italy; Angelo Bianchi Bonomi Hemophilia and
Thrombosis Center, IRCCS, Maggiore Hospital, University of Milan,
Italy; Division of Cardiology, Ospedale Niguarda, Milan; Division of
Cardiology, IRCCS, Policlinico San Matteo, Pavia, Italy; Division of
Cardiology, Ospedale Legnano, Italy; Charles A. Dana Research
Institute, Department of Medicine, Beth Israel Deaconess Medical Center
and Harvard Medical School; and Department of Biology, Massachusetts
Institute of Technology, Cambridge, MA.
Higher levels of tissue factor (the initiator of blood coagulation)
have been found in coronary atherosclerotic plaques of patients with
unstable coronary artery disease, but it is not established whether
they are associated with a different thrombotic response to in vivo
plaque rupture. In 40 patients undergoing directional coronary
atherectomy, prothrombin fragment 1 + 2, a marker of thrombin
generation, was measured in intracoronary blood samples obtained
proximally and distally to the coronary atherosclerotic plaque before
and after the procedure. Before the procedure, plasma prothrombin
fragment 1 + 2 levels were significantly increased across the lesion
in patients with unstable, but not in those with stable, coronary
disease (unstable, median increase, 0.37 nM; range, The rupture or fissuring of coronary
atherosclerotic plaque and subsequent thrombosis are considered the key
events in the pathogenesis of unstable angina or acute myocardial
infarction.1,2 Plaque disruption frequently occurs during
the course of atherosclerosis, but only some ruptured plaques develop
thrombosis.3,4 Tissue factor (the primary initiator of
blood coagulation) is contained in human coronary atherosclerotic
plaques and is functionally active in vitro.5-7 There are
larger amounts of functionally active tissue factor in the plaque of
patients with unstable coronary artery disease (unstable angina and
myocardial infarction) than in those with stable angina,7
roughly corresponding to the different tendency of stable and unstable
disease to be associated with coronary thrombosis. Hence, the different
thrombotic response to plaque rupture has been attributed to variations
in tissue factor content. However, there is no in vivo evidence of any
quantitative association between tissue factor content and thrombin
generation in response to plaque disruption.
By cutting the atherosclerotic plaque, directional coronary atherectomy
exposes the plaque content to flowing blood, thus mimicking spontaneous
plaque rupture. This procedure also provides a unique opportunity to
obtain fresh samples of plaque tissue that can be biochemically
analyzed and related to the degree of coagulation activation in
coronary blood. This study was undertaken to evaluate whether a
different amount of tissue factor in atherosclerotic plaques is
associated with a different degree of thrombin generation in the
coronary blood of patients with coronary artery disease.
Study population
Intracoronary blood sampling
Blood processing and measurement of thrombin generation Samples were collected through the sampling catheter directly into refrigerated plastic tubes containing an anticoagulant mixture consisting of a thrombin inhibitor, EDTA, and aprotinin. The anticoagulant blood ratio used was 1:9 (vol/vol). Blood samples were immediately centrifuged at 2500g for 25 minutes at 4°C; the plasma was frozen on dry ice and stored at 80°C until use. All samples were analyzed by laboratory personnel who had no knowledge of
the clinical data. Plasma levels of prothrombin fragment 1 + 2 were
measured by means of a previously described double-antibody radioimmunoassay, which has a coefficient of variation of
8%.8
Coronary angiography and directional coronary atherectomy Selective coronary arteriography was performed in multiple views using the Judkins technique. Greater than 70% narrowing in the diameter of the coronary arteries was considered significant coronary artery stenosis. Patients were classified as having 1-, 2-, or 3-vessel disease according to the number of vessels with significant coronary stenoses. Angiographic morphology of the lesions was prospectively assessed and was considered complex if the lesions had irregular borders, overhanging edges, ulcerations, or thromboses.Before directional coronary atherectomy, patients were given 160 to 325 mg aspirin and heparin U/kg 70 adjusted as needed to maintain an activated clotting time of more than 250 seconds. Directional coronary atherectomy was performed using standard procedures. Briefly, the atherectomy device was directed over a previously inserted 300-cm-long guide wire and positioned at the level of the stenosis, and the support balloon was then inflated up to 1 atm. The cutter was then retracted, and the inflation pressure of the balloon was increased to a maximum of 3 atm. The driving motor was started, and the rotating cutter slowly was advanced to cut and collect the protruding plaque in the collection chamber located at the tip of the catheter. After each pass, the balloon was deflated and either removed or repositioned. Plaque processing and measurement of tissue factor procoagulant activity After thawing, the lipid-bound proteins in the plaques were solubilized using 1% Triton X-100 in phosphate-buffered saline for 2 hours at room temperature and then were centrifuged at 50 000g for 1 hour at 20°C. Tissue factor activity was analyzed in the supernatant using a previously published chromogenic factor Xa generation assay.7Statistical analysis The descriptive statistics include mean values and standard deviations, or median values and ranges, as appropriate. Between-group differences were tested by using the Student unpaired t test or the Mann Whitney U test. Prevalences were compared by means of the 2 test. Correlation between
tissue factor activity and prothrombin fragment 1 + 2 was calculated
as Spearman rank correlation ( ). All tests were 2-tailed, and
P < .05 was regarded as statistically significant.
Clinical and angiographic characteristics of the study population
are reported in Table 1. There was a
higher prevalence of lesions with complex morphology in the patients
with unstable coronary artery disease than in those with stable disease
(P < .0001).
Before directional coronary atherectomy, there was no difference in the
plasma prothrombin fragment 1 + 2 levels measured proximally to the
lesion between the patients with stable or unstable coronary artery
disease, whereas higher fragment levels were found distally to the
lesion in unstable patients (P = .0045). No significant increase in fragment 1 + 2 levels was observed across the lesion in
stable patients, whereas a significant increase was observed in
unstable patients (Table 2)
(P = .002). The median change in prothrombin fragment
levels across the lesion was significantly greater in patients with
unstable coronary artery disease (P = .0021); there was a
median increase of 0.37 nM (range,
After plaque removal, there was no difference in the fragment
levels measured proximally to the lesion between the patients with
stable and unstable coronary artery disease, whereas significantly higher levels were found distally to the lesion in patients with unstable disease (P = .027). No significant increase in
fragment 1 + 2 was observed across the excised lesion in stable
patients, whereas a significant increase was observed in unstable
patients (Table 2) (P = .043). The change in fragment
levels across the lesion was significantly greater in the patients with
unstable coronary disease (P = .036), with a median
increase of 0.25 nM (range, Median weights were as follows: extracted plaque, 5.7 mg (range,
0.15-15.1 mg); coronary plaque of patients with stable disease, 4.5 mg
(range, 0.15-9.7 mg); coronary plaque of patients with unstable
disease, 7.2 mg (range, 0.8-15.1 mg). Tissue factor activity per
milligram plaque weight ranged from 0 to 5.3 mU/mg. It was greater in
the plaques extracted from patients with unstable disease than from
patients with stable disease (0.258 mU/mg [range, 0.08-5.30 mU/mg] vs
0.156 mU/mg [range, 0-1.94 mU/mg]; P = .011). There was
a statistically significant positive correlation between the tissue
factor activity of the removed plaque and the increase in thrombin
generation across the lesion after the procedure (
Tissue factor has been detected within the necrotic cores of endo-atherectomy specimens from patients with carotid atherosclerosis9 and in atherectomy specimens from patients with coronary artery disease.5-7 Furthermore, the tissue factor found in atherosclerotic plaques has been shown to be functionally active in vitro because it is capable of generating activated factor X.7 In an ex vivo model, Toschi et al10 and Badimon et al11 used a perfusion chamber to evaluate the platelet and fibrinogen deposition on aortic atherosclerotic plaques exposed to flowing blood, and they found a positive correlation between the amount of tissue factor detected by means of in situ binding assays and both platelet and fibrinogen deposition. Tissue factor staining of the lipid-rich core was more intense than that of all of the other plaque components, and there was also a higher level of platelet and fibrinogen deposition. Finally, a recent study has shown that a thrombus could be histologically detected only in coronary atherectomy specimens characterized by immunohistochemically detectable tissue factor.6 All these findings strongly support the view that the presence and amount of functional tissue factor in coronary atherosclerotic plaques may be critical for thrombus formation in acute coronary events. However, it is still unknown whether higher levels of tissue factor in coronary plaques in vivo is associated with increased thrombus formation after plaque rupture. This study confirms that tissue factor activity is greater in the coronary atherosclerotic plaques extracted from patients with unstable angina or myocardial infarction than in those extracted from patients with stable angina. The new finding is that the local (intracoronary) measurement of thrombin generation makes it possible to demonstrate that greater tissue factor activity in atherosclerotic plaque is associated with a greater increase in thrombin generation across the lesion, before and after plaque disruption induced by directional coronary atherectomy. Of the patients with unstable coronary artery disease, 71% had abnormal increases in thrombin generation before the procedure and 65% had them after the procedure; of those with stable disease, 27% had abnormal increases in thrombin generation across the lesion before the procedure and 25% had them after the procedure. Perhaps the greater increase in thrombin generation observed before the procedure in patients with unstable coronary artery disease occurred because most of them already had a ruptured plaque that exposed tissue factor. Patients with stable angina have smooth, fibrous, nonulcerated plaques with little exposure of tissue factor. We surmise that in patients with unstable plaque, the thrombogenic material is already exposed and so the lesions induced by atherectomy do not further increase such a thrombogenic stimulus. On the other hand, in patients who have stable plaque at baseline, the lesions induced by atherectomy theoretically expose a new surface to prothrombin activation, but the local thrombotic stimulus is too weak and inadequate to reach the level of prothrombin activation seen in unstable patients. The highest values of thrombin generation across the lesion were observed in patients with unstable coronary artery disease after atherectomy. We hypothesize that this strong thrombogenic stimulus may lead to the thrombotic complications occasionally observed during percutaneous coronary interventions despite intensive antithrombotic therapy. On the whole, these findings further support the notion that plaque rupture and exposure of the atheromatous core is not the only precipitating event in determining coronary thrombosis. The nature of the plaque components exposed to flowing blood,12 together with the local rheologic and systemic blood factors13 in unstable patients, are also critical in determining the extent of the prothrombic response. In this respect, tissue factor appears to be a critical plaque component.
Submitted January 3, 2001; accepted June 20, 2001.
The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.
Reprints: Diego Ardissino, Divisione di Cardiologia, Ospedale Maggiore, Universita' degli Studi di Parma, Via Gramsci 14, 43100 Parma, Italy; e-mail: ardis001{at}planet.it.
1. Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute ischemic syndromes. N Engl J Med. 1992;326:242-250[Medline] [Order article via Infotrieve]. 2. Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute ischemic syndromes. N Engl J Med. 1992;326:310-318[Medline] [Order article via Infotrieve].
3.
Falk E.
Unstable angina with fatal outcome: dynamic coronary thrombosis leading to infarction and/or sudden death.
Circulation.
1985;71:699-708 4. Davies MJ, Thomas AC. Thrombosis and acute coronary coronary artery lesions in sudden cardiac ischemic death. N Engl J Med. 1984;310:1137-1140[Abstract].
5.
Annex BH, Denning SM, Channon KM, et al.
Differential expression of tissue factor protein in directional atherectomy specimens from patients with stable and unstable coronary syndromes.
Circulation.
1995;91:619-622
6.
Marmur JD, Thiruvikraman SV, Fyfe BS, et al.
Identification of active tissue factor in human coronary atheroma.
Circulation.
1996;94:1226-1232 7. Ardissino D, Merlini PA, Ariens R, Coppola R, Bramucci E, Mannucci PM. Tissue-factor antigen and activity in human coronary atherosclerotic plaque. Lancet. 1997;349:769-771[CrossRef][Medline] [Order article via Infotrieve].
8.
Teitel JM, Bauer KA, Lau HK, Rosenberg RD.
Studies of the prothrombin activation pathway utilizing radioimmunoassays for the F2/prothrombin fragment 1+2 and thrombin/antithrombin complex.
Blood.
1982;59:1086
9.
Wilcox JN, Smith KM, Schwartz SM, Gordon D.
Localization of tissue factor in the normal vessel wall and in the atherosclerotic plaque.
Proc Natl Acad Sci U S A.
1989;86:2839-2843
10.
Toschi V, Fallon JT, Gallo R, et al.
Tissue factor modulates the thrombogenicity of human atherosclerotic plaques.
Circulation.
1997;95:594-599 11. Badimon JJ, Lettino M, Toschi V, et al. Local inhibition of tissue factor reduces the thrombogenicity of disrupted human atherosclerotic plaques: effect of tissue factor pathway inhibitor on plaque thrombogenicity under flow conditions. Circulation. 1999;99:17801787. 12. Fernandez-Ortis A, Badimon JJ, Falk E, et al. Characterization of the relative thrombogenicity of atherosclerotic plaque components: implications for the consequences of plaque rupture. J Am Coll Cardiol. 1994;23:1562-1569[Abstract]. 13. Meade TH, Miller GJ, Rosenberg RD. Characteristics associated with the risk of arterial thrombosis. In: Verstraete M,Fuster V,Topol EJ, eds. Cardiovascular Thrombosis: Thrombocardiology and Thromboneurology. Philadelphia, PA: Lippincott-Raven; 1998:77-89.
© 2001 by The American Society of Hematology.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
![]() |
S. Eligini, F. Violi, C. Banfi, S. S. Barbieri, M. Brambilla, M. Saliola, E. Tremoli, and S. Colli Indobufen inhibits tissue factor in human monocytes through a thromboxane-mediated mechanism Cardiovasc Res, January 1, 2006; 69(1): 218 - 226. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. K. MacCallum Markers of Hemostasis and Systemic Inflammation in Heart Disease and Atherosclerosis in Smokers Proceedings of the ATS, April 1, 2005; 2(1): 34 - 43. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Ohkawara, T. Ishibashi, T. Sakamoto, K. Sugimoto, K. Nagata, K. Yokoyama, N. Sakamoto, M. Kamioka, I. Matsuoka, S. Fukuhara, et al. Thrombin-induced Rapid Geranylgeranylation of RhoA as an Essential Process for RhoA Activation in Endothelial Cells J. Biol. Chem., March 18, 2005; 280(11): 10182 - 10188. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. V. M. Rao and U. R. Pendurthi Tissue Factor-Factor VIIa Signaling Arterioscler Thromb Vasc Biol, January 1, 2005; 25(1): 47 - 56. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. K. Mandal, A. Iakhiaev, U. R. Pendurthi, and L. V. M. Rao Acute cholesterol depletion impairs functional expression of tissue factor in fibroblasts: modulation of tissue factor activity by membrane cholesterol Blood, January 1, 2005; 105(1): 153 - 160. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. Llorente-Cortes, M. Otero-Vinas, S. Camino-Lopez, O. Llampayas, and L. Badimon Aggregated Low-Density Lipoprotein Uptake Induces Membrane Tissue Factor Procoagulant Activity and Microparticle Release in Human Vascular Smooth Muscle Cells Circulation, July 27, 2004; 110(4): 452 - 459. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Butenas, T. Orfeo, M. T. Gissel, K. E. Brummel, and K. G. Mann The Significance of Circulating Factor IXa in Blood J. Biol. Chem., May 28, 2004; 279(22): 22875 - 22882. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Jeanpierre, T. Le Tourneau, I. Six, C. Zawadzki;, E. Van Belle, M. D. Ezekowitz, R. Bordet, S. Susen, B. Jude, and D. Corseaux Dietary Lipid Lowering Modifies Plaque Phenotype in Rabbit Atheroma After Angioplasty: A Potential Role of Tissue Factor Circulation, October 7, 2003; 108(14): 1740 - 1745. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. H. M. Moons, R. J. G. Peters, N. R. Bijsterveld, J. J. Piek, M. H. Prins, G. P. Vlasuk, W. E. Rote, and H. R. Buller Recombinant nematode anticoagulant protein c2, an inhibitor of the tissue factor/factor VIIa complex, in patients undergoing elective coronary angioplastyAppendix J. Am. Coll. Cardiol., June 18, 2003; 41(12): 2147 - 2153. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Sambola, J. Osende, J. Hathcock, M. Degen, Y. Nemerson, V. Fuster, J. Crandall, and J. J. Badimon Role of Risk Factors in the Modulation of Tissue Factor Activity and Blood Thrombogenicity Circulation, February 25, 2003; 107(7): 973 - 977. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Kluft, R. Kleemann, and M.P.M. de Maat How best to counteract the enemies? By controlling inflammation in the coronary circulation Eur. Heart J. Suppl., November 1, 2002; 4(suppl_G): G53 - G65. [Abstract] [PDF] |
||||
![]() |
N. M. Ananyeva, D. V. Kouiavskaia, M. Shima, and E. L. Saenko Intrinsic pathway of blood coagulation contributes to thrombogenicity of atherosclerotic plaque Blood, May 29, 2002; 99(12): 4475 - 4485. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Copyright © 2001 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||